TY  - JOUR
AU  - Megías-Vericat, Juan Eduardo
AU  - Martínez-Cuadrón, David
AU  - López, Joaquín Martínez
AU  - Bergua, Juan Miguel
AU  - Tormo, Mar
AU  - Serrano, Josefina
AU  - González, Ataulfo
AU  - de Oteyza, Jaime Pérez
AU  - Vives, Susana
AU  - Vidriales, Belén
AU  - Herrera, Pilar
AU  - Vera, Juan Antonio
AU  - Martínez, Aurelio López
AU  - de la Fuente, Adolfo
AU  - Amador, Ma Lourdes
AU  - Hernández-Rivas, José-Ángel
AU  - Fernández, Ma Ángeles
AU  - Cerveró, Carlos Javier
AU  - Morillo, Daniel
AU  - Campo, Pilar Hernández
AU  - Gorrochategui, Julián
AU  - Primo, Daniel
AU  - Rojas, José Luis
AU  - Guenova, Margarita
AU  - Ballesteros, Joan
AU  - Sanz, Miguel
AU  - Montesinos, Pau
PY  - 2019
DO  - 10.4084/MJHID.2019.016
SN  - 2035-3006
UR  - https://hdl.handle.net/10668/27685
T2  - Mediterranean journal of hematology and infectious diseases
AB  - Induction schedules in acute myeloid leukemia (AML) are based on combinations of cytarabine and anthracyclines. The choice of the anthracycline employed has been widely studied in multiple clinical trials showing similar complete remission rates....
LA  - en
KW  - Acute myeloid leukemia
KW  - Anthracycline
KW  - Daunorubicin
KW  - Idarubicin
KW  - Mitoxantrone
KW  - Personalized medicine
KW  - ex-vivo test
TI  - Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia.
TY  - research article
VL  - 11
ER  -